Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.

Journal of medical virology - 1 May 2026

Yan Lu, Wubuliaishan Maimaitijiang, Kou Xiaoni, Tuerxun Maimaitiaili, Yang Mingbo, Ji Fanpu, He Yingli, Wang Jiuping, Zhu Longdong, Gao Xiaohong, Jing Fuchun, Ding Xiangchun, Du Hong, Zhang Ye, Jiang Hong

Abstract excerpt

To assess the sustained virologic response (SVR12) and safety profile of 12-week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)-infected patients across genotypes in Northwest China. This prospective cohort study (2023-2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis C Prevention Guidelines (2022). Participants received daily oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Treatment Outcome

Source

Identifiers

PMID: 42159424
DOI: 10.1002/jmv.70978

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.PMID 42159424Read ↗

[Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].Semantic proximity Read ↗

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.Semantic proximity Read ↗

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.Semantic proximity Read ↗

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.Semantic proximity Read ↗

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.Semantic proximity Read ↗

Sofosbuvir-based therapies achieved satisfactory virological response in Chinese with genotypes 3 and 6 infection: a real-world experience from a centreSemantic proximity Read ↗

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study.Semantic proximity Read ↗

Chronic Hepatitis C and comorbidities: real-world study to evaluate impact in outcomes after treatment with sofosbuvir-based regimensSemantic proximity Read ↗

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.Semantic proximity Read ↗

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: Real-world experience from Southwest ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.